Patents by Inventor Adam J. Morgan

Adam J. Morgan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20230355629
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: December 9, 2022
    Publication date: November 9, 2023
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS
    Publication number: 20220306636
    Abstract: Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.
    Type: Application
    Filed: February 6, 2020
    Publication date: September 29, 2022
    Inventors: Robert S. Lewis, Mahender Reddy Karla, Kathryn E. Kavouris, Yong Dong, Adam J. Morgan, Cameron J. Cowden
  • PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS
    Publication number: 20220213105
    Abstract: Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.
    Type: Application
    Filed: August 12, 2021
    Publication date: July 7, 2022
    Inventors: Robert S. Lewis, Mahender Reddy Karla, Kathryn E. Kavouris, Yong Dong, Adam J. Morgan, Cameron J. Cowden
  • DEUTERATED CFTR POTENTIATORS
    Publication number: 20220041557
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Application
    Filed: December 14, 2020
    Publication date: February 10, 2022
    Applicant: Vertex Pharmaceuticals (Europe) Limited
    Inventor: Adam J. Morgan
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20210403407
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: February 1, 2021
    Publication date: December 30, 2021
    Inventors: Roger D. Tung, Adam J. Morgan
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20210330674
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: December 10, 2020
    Publication date: October 28, 2021
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • Deuterated CFTR potentiators
    Patent number: 10894773
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: January 19, 2021
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventor: Adam J. Morgan
  • DEUTERATED CFTR POTENTIATORS
    Publication number: 20200290971
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Application
    Filed: October 22, 2019
    Publication date: September 17, 2020
    Applicant: Vertex Pharmaceuticals (EUROPE) Limited
    Inventor: Adam J. Morgan
  • Deuterated CFTR potentiators
    Patent number: 10759721
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein each X and each R is defined within. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: September 1, 2020
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventors: Adam J. Morgan, Roger D. Tung
  • DEUTERATED CFTR POTENTIATORS
    Publication number: 20200031776
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein each X and each R is defined within. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 30, 2020
    Inventors: Adam J. Morgan, Roger D. Tung
  • Deuterated CFTR potentiators
    Patent number: 10479766
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: November 19, 2019
    Assignee: Verex Pharmaceuticals (Europe) Limited
    Inventor: Adam J. Morgan
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20190308976
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: March 11, 2019
    Publication date: October 10, 2019
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • DEUTERATED PALBOCICLIB
    Publication number: 20190225605
    Abstract: This invention relates to novel pyrido[2,3-d]pyrimidinones of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CDK-4 and/or CDK-6 inhibitor.
    Type: Application
    Filed: November 13, 2018
    Publication date: July 25, 2019
    Inventor: Adam J. Morgan
  • DEUTERATED CFTR POTENTIATORS
    Publication number: 20190169129
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Application
    Filed: July 12, 2018
    Publication date: June 6, 2019
    Applicant: Vertex Pharmaceuticals (EUROPE) Limited
    Inventor: Adam J. Morgan
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20190100484
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: August 6, 2018
    Publication date: April 4, 2019
    Inventors: Roger D. Tung, Adam J. Morgan, I. Robert Silverman
  • Deuterated CFTR potentiators
    Patent number: 10047053
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: August 14, 2018
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventor: Adam J. Morgan
  • 4-hydroxybutyric acid analogs
    Patent number: 10040748
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: August 7, 2018
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Adam J. Morgan
  • DEUTERATED CFTR POTENTIATORS
    Publication number: 20180086711
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Application
    Filed: November 30, 2017
    Publication date: March 29, 2018
    Applicant: Vertex Pharmaceuticals (EUROPE) Limited
    Inventor: Adam J. Morgan
  • DEUTERATED PALBOCICLIB
    Publication number: 20180051022
    Abstract: This invention relates to novel pyrido[2,3-d]pyrimidinones of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CDK-4 and/or CDK-6 inhibitor.
    Type: Application
    Filed: June 29, 2017
    Publication date: February 22, 2018
    Inventor: Adam J. Morgan
  • Deuterated ibrutinib
    Patent number: 9777009
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: October 3, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Adam J. Morgan